Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciences has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Pacira BioSciences's Interest Coverage for the quarter that ended in Jun. 2026 was 3.82.
Pacira BioSciences's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.54.
As of today, Pacira BioSciences's Altman Z-Score is 1.96.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Pacira BioSciences has the Financial Strength Rank of 5.
Pacira BioSciences Financial Strength Related Terms
PCRX vs ALVO, BIOA, COLL: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Financial Strength vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Pacira BioSciences has a Z-score of 1.96, indicating it is in Grey Zones. This implies that Pacira BioSciences is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 1.96 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Financial Strength of 5 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Pacira BioSciences and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Pacira BioSciences' Financial Strength has ranged from 5.00 to 8.00.
Is Pacira BioSciences' Financial Strength too high?
Pacira BioSciences' current Financial Strength of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. Overall, Pacira BioSciences has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Financial Strength compare to ALVO and BIOA?
Pacira BioSciences' Financial Strength of 5 can be compared against companies in the Drug Manufacturers industry. Historically, Pacira BioSciences' own Financial Strength has ranged from 5.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Financial Strength is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.15, compared to a current price of $23.83 — trading 18.3% below its estimated fair value. The current Financial Strength is 5, which is 17% below median its 10-year median of 6.00. Pacira BioSciences' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Financial Strength is 5 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $23.83 is trading 18.3% below its estimated GF Value™ of $29.15.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Financial Strength: 5 (17% below median its 10-year median of 6.00)
GF Value™: $29.15 vs. price of $23.83 (18.3% below fair value)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
81GF Score
Get the complete analysis for PCRX
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
